CGTX
COGNITION THERAPEUTICS INC
Next earnings Aug 5, 2026 · consensus $-0.06 EPS
Last earnings -5.7% on 2026-05-07
$1.12
▼ -0.89%$1.12▲ +273.33%
over 1Y
L $0.30EODHDH $3.06
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.9%
1W-0.9%
1M-5.9%
3M+53.4%
YTD-23.8%
1Y+273.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.41x).
Return on equity -68.5% · latest
COGNITION THERAPEUTICS INC shows limited reported revenue, and -68.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$28.6M | -$43.6M | -$50.7M | -$54.0M | -$47.8M |
| Net income | -$11.7M | -$21.4M | -$25.8M | -$34.0M | -$23.5M |
| Diluted EPS | -$3.13 | -$0.91 | -$0.86 | -$0.86 | -$0.32 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$63.3M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.5%
FCF yield-24.6%
Quality & risk
ROIC (est.)-110.2%
Free cash flow-$24.6M
Total debt—
Net cash$36.8M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+44.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗8-KPeriod ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-042026-06-04open ↗8-KPeriod ending 2026-05-212026-05-21open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-072026-05-07open ↗4Period ending 2026-05-012026-05-04open ↗
Frequently asked
- Is COGNITION THERAPEUTICS INC (CGTX) a buy?
- CGTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.41x).
- What is COGNITION THERAPEUTICS INC's quality score?
- CGTX scores 59.15384615384615/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001455365, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 5:55:21 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.